Zai Lab Limited American Depositary Shares (ZLAB)
Company News
Zai Lab's Double Whammy: Earnings Miss, Phase 3 Setback
Chinese biopharma firm Zai Lab experienced a significant stock decline after disappointing Phase 3 trial results for its gastric cancer drug bemarituzumab and underwhelming quarterly earnings, with weak sales of core products impacting investor confidence.
Bispecific Antibody Clinical Trial Pipeline Gains Momentum: 180+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight
Over 180 companies are developing 250+ bispecific antibodies targeting complex chronic diseases like cancer and autoimmune disorders, with innovative dual-targeting molecules offering superior therapeutic precision and efficacy.
What Makes Zai Lab Limited Unsponsored ADR (ZLAB) a New Buy Stock
Zai Lab Limited Unsponsored ADR (ZLAB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Why Wall Street Thinks This Artificial Intelligence (AI) Stock Could Skyrocket 140% Over the Next 12 Months
Cathie Wood and Bill Gates like this stock, too.